BIOGEN HIRLULOG LOWER INCIDENCE OF BLEEDING COMPLICATIONS v. HEPARIN IS DEEMED INSUFFICIENT CLINICAL RESULT; FIRM REDEPLOYING RESOURCES TO BETA INTERFERON
Executive Summary
A lower incidence of bleeding complications for Biogen's Hirulog compared to heparin following angioplasty was not enough of a clinical result to convince Biogen to continue developing the synthetic leech protein derivative hirudin. Cambridge, Mass.-based Biogen announced Oct. 31 that it is abandoning Hirulog following a preliminary review of Phase III trial results.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: